Literature DB >> 1909871

Organization of the gene encoding human lysosomal beta-galactosidase.

H Morreau1, E Bonten, X Y Zhou, A D'Azzo.   

Abstract

Human beta-galactosidase precursor mRNA is alternatively spliced into an abundant 2.5-kb transcript and a minor 2.0-kb species. These templates direct the synthesis of the classic lysosomal beta-D-galactosidase enzyme and of a beta-galactosidase-related protein with no enzymatic activity. Mutations in the beta-galactosidase gene result in the lysosomal storage disorders GM1-gangliosidosis and Morquio B syndrome. To analyze the genetic lesions underlying these syndromes we have isolated the human beta-galactosidase gene and determined its organization. The gene spans greater than 62.5 kb and contains 16 exons. Promoter activity is located on a 236-bp Pst I fragment which works in a direction-independent manner. A second Pst I fragment of 851 bp located upstream from the first negatively regulates initiation of transcription. The promoter has characteristics of a housekeeping gene with GC-rich stretches and five potential SP1 transcription elements on two strands. We identified multiple cap sites of the mRNA, the major of which maps 53 bp upstream from the translation initiation codon. The portion of the human pre-mRNA undergoing alternative splicing is encoded by exons II-VII. Sequence analysis of equivalent mouse exons showed an identical genomic organization. However, translation of the corresponding differentially spliced murine transcript is interrupted in its reading frame. Thus, the mouse gene cannot encode a beta-galactosidase-related protein in a manner similar to the human counterpart. Differential expression of the murine beta-galactosidase transcript is observed in different mouse tissues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909871     DOI: 10.1089/dna.1991.10.495

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  8 in total

1.  Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.

Authors:  S Zhang; R Bagshaw; W Hilson; Y Oho; A Hinek; J T Clarke; J W Callahan
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Isolation and characterization of the normal canine beta-galactosidase gene and its mutation in a dog model of GM1-gangliosidosis.

Authors:  Z H Wang; B Zeng; H Shibuya; G S Johnson; J Alroy; G M Pastores; S Raghavan; E H Kolodny
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

3.  Modulating action of the new polymorphism L436F detected in the GLB1 gene of a type-II GM1 gangliosidosis patient.

Authors:  Anna Caciotti; Tiziana Bardelli; John Cunningham; Alessandra D'Azzo; Enrico Zammarchi; Amelia Morrone
Journal:  Hum Genet       Date:  2003-03-19       Impact factor: 4.132

4.  Mutations in the lysosomal beta-galactosidase gene that cause the adult form of GM1 gangliosidosis.

Authors:  S Chakraborty; M A Rafi; D A Wenger
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

5.  Three novel beta-galactosidase gene mutations in Han Chinese patients with GM1 gangliosidosis are correlated with disease severity.

Authors:  Chi-Fan Yang; Jer-Yuarn Wu; Fuu-Jen Tsai
Journal:  J Biomed Sci       Date:  2010-09-30       Impact factor: 8.410

6.  Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis.

Authors:  Douglas R Martin; Brigitte A Rigat; Polly Foureman; G S Varadarajan; Misako Hwang; Barbara K Krum; Bruce F Smith; John W Callahan; Don J Mahuran; Henry J Baker
Journal:  Mol Genet Metab       Date:  2008-03-18       Impact factor: 4.797

7.  Assignment of human beta-galactosidase-A gene to 3p21.33 by fluorescence in situ hybridization.

Authors:  T Takano; Y Yamanouchi
Journal:  Hum Genet       Date:  1993-10       Impact factor: 4.132

8.  SR proteins and the nonsense-mediated decay mechanism are involved in human GLB1 gene alternative splicing.

Authors:  Raül Santamaria; Lluïsa Vilageliu; Daniel Grinberg
Journal:  BMC Res Notes       Date:  2008-12-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.